MSLN and ovarian carcinoma: In addition, the binding of mesothelin to CA125, an ovarian cancer biomarker, and upregulation of metalloproteinases has been reported to facilitate metastatic spread, making mesothelin an interesting target in ovarian cancer [18, 19, 49, 50].